Alzheimer's Disease
NIH awards $3.3 million for oral disease-modifying Alzheimer’s, Parkinson’s therapeutic
The NIH has awarded a $3.3 million grant to advance a novel, oral silent allosteric modulator intended to treat Alzheimer’s and Parkinson’s diseases, according to the manufacturer.
Dementia more frequently diagnosed in older adults within a year of fall-related injury
Falling was associated with an increased risk for a diagnosis of Alzheimer’s disease or other dementias in older adults, according to a recent analysis in JAMA Network Open.
The promise of anti-amyloid therapies: A new era in Alzheimer’s treatment
The world is facing an impending tsunami as the number of people developing Alzheimer’s disease continues to grow.
The inside story of Cobenfy
Obscured by the celebratory congratulations and profuse praise of the scientific advance marked by the FDA’s approval of KarXT, now branded Cobenfy, is the revealing and instructive story of how this novel therapeutic agent came to fruition.
Tiziana Life Sciences receives $4M from NIH to advance intranasal Alzheimer’s therapy
A New York-based biotechnology company has received a $4 million grant from the NIH’s National Institute on Aging to advance a novel intranasal therapeutic to treat Alzheimer’s disease, according to a press release from the manufacturer.
Q&A: New Alzheimer’s dataset allows ‘whispers from the brain’ to assist in early detection
The future of Alzheimer’s disease detection and treatment may lie in AI-based datasets encompassing an abundance of real-world evidence from a large number of patients, an expert said.
Diagnostic firm receives $7 million to advance novel Alzheimer’s biomarker platform
C2N Diagnostics has been awarded more than $7 million from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator initiative to advance a novel platform intended to boost Alzheimer’s disease biomarker detection.
VIDEO: More data support first FDA-approved drug to treat Alzheimer’s-related agitation
PHILADELPHIA — In this Healio Video Perspective from the Alzheimer’s Association International Conference, Johan Luthman, PhD, discusses new data from post hoc analyses evaluating the efficacy of Rexulti for Alzheimer’s-related agitation.
Diabetes drug linked to reduced risk for dementia, Parkinson’s disease
The use of sodium-glucose cotransporter 2 inhibitors reduced the risk for multiple neurodegenerative diseases in adults with type 2 diabetes, according to study results published in Neurology.
Study finds no link between late-life depression, global amyloid deposition
ORLANDO, Fla. — Among a cohort of patients within the Atherosclerosis Risk in Communities study, no link was found between late-life depression and global amyloid deposition, according to a poster at the American Neurological Association.